From the Journals

Lab Markers May Guide Lupus Biologic Use

Analysis of 31 trials links serologic activity and disease severity to improved response.

Share

A comprehensive meta-analysis in Lupus Science & Medicine analyzed 31 trials with over 17,000 lupus patients to determine who benefits most from biologic therapies. Findings showed these therapies improve clinical response in patients with serologically active disease, especially those with anti-double-stranded DNA antibodies and low complement levels. Higher baseline disease activity also correlated with better outcomes. Biologics targeting B-cell activating factor showed consistent efficacy, while treatment safety indicated minimal adverse events, highlighting the importance of routine serologic markers in treatment decisions.

Original Source(s)

Lab Markers May Guide Lupus Biologic Use

  • by Olivia Anderson

  • March 19, 2026

Related Content

The Missing Step in Pediatric Lupus Care

Survey data show gaps between rheumatologists’ beliefs and clinical practice in screening and neuropsychological evaluation for childhood-onset systemic lupus erythematosus

Knee OA Trial Tests Diacerein

Researchers compared diacerein and placebo in a 24-week randomized study involving knee osteoarthritis with MRI-confirmed effusion-synovitis.

Dry Eye Across Autoimmune Diseases

The nationwide analysis found the highest rates of dry eye disease among patients with Sjögren’s syndrome.